A traditional Chinese medicine compound composition for treating spleen deficiency and phlegm turbidity type hypertension

Abstract

The present invention provides a traditional Chinese medicine compound composition for treating spleen deficiency and phlegm turbidity type hypertension and its preparation method, which has the effect of improving patients' dizziness and headache symptoms and preventing the occurrence of cardiovascular and cerebrovascular diseases in hypertensive patients. To achieve the above objects, the technical solution of the present invention is as follows: the composition is as follows by mass: 20-40 parts of raw astragalus, 10-20 parts of Poria, 10-20 parts of Alisma, 10-20 parts of Pueraria, 10-20 parts of Salvia miltiorrhiza, 5-10 parts of Chuanxiong, 10-20 parts of Leonurus, and 10-20 parts of Corn Silk. The preparation method comprises the following steps: adding raw astragalus, Poria, Rhizoma Alismatis, Radix Puerariae, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Herba Leonurus, and Stigma Corni to the above-mentioned mass fractions and adding 5 times the weight volume of water; decocting twice, each time for 1 to 2 hours; combining the decoctions; filtering and concentrating the filtrate; adding 80% ethanol by volume for treatment; allowing to stand; filtering and recovering the filtrate; and concentrating at 60°C to a relative density of 1.30 to 1.36 to obtain an extract. The extract can be prepared into a dosage form such as an ointment, oral liquid, or granule by combining the extract with a pharmaceutically acceptable carrier.

Description

Technical Field

[0001] The present invention relates to the technical field of Chinese medicinal compound compositions, and more particularly to a Chinese medicinal compound composition for treating spleen deficiency and phlegm turbidity type hypertension. Background Art

[0002] Hypertension is a clinical syndrome characterized by elevated systemic arterial pressure, accompanied by damage to multiple organs, including the heart, brain, and kidneys. It can be divided into primary and secondary hypertension. Approximately 90% of cases of hypertension are primary. Elevated blood pressure can cause symptoms such as dizziness, headache, and neck stiffness. A 2015 multicenter, randomized, double-blind study in the United States showed that hypertension is the leading cause of disability-adjusted life years (DALYs) worldwide. The revised "Guidelines for the Prevention and Treatment of Hypertension in my country" in 2018 noted that the prevalence of hypertension among adults in my country has reached 27.9%. According to epidemiological statistics, with accelerated urbanization and the influence of unhealthy lifestyles, the number of people with hypertension in my country continues to rise, becoming a major obstacle to achieving the Healthy China strategy. Therefore, breakthrough progress in the prevention and treatment of hypertension is urgently needed.

[0003] Clinical treatment for hypertension currently relies mainly on Western medicine, but patients are prone to varying degrees of drug resistance and adverse reactions after long-term medication, resulting in poor blood pressure control and further reducing patient compliance. In the process of seeking solutions to the pain points of traditional Western antihypertensive drugs, we found that natural products represented by Chinese medicine have the advantages of diverse chemical structures and biological activities and few adverse reactions. Traditional Chinese medicine and Chinese medicine compound prescriptions guided by the theoretical system of traditional Chinese medicine can treat diseases from the perspective of multi-component, multi-pathway, and multi-target synergistic effects. Therefore, exploring new antihypertensive plans based on traditional Chinese medicine can not only help lower patients' blood pressure, but also provide a new treatment approach for patients who are intolerant to Western antihypertensive drugs.

[0004] Hypertension falls under the categories of "vertigo" and "headache" in Traditional Chinese Medicine. Traditional Chinese Medicine considers the spleen and stomach to be the hubs for the ascending and descending of Qi. When the spleen and stomach are weak, their ascending and descending functions are abnormal, disrupting the Qi flow of the internal organs. This prevents the body's Qi and blood essence from ascending, while insufficiently nourishing the head and orifices with phlegm and turbid waste. Clear Qi fails to ascend, and the head and orifices are deprived of nourishment. Turbid Qi fails to descend, obscuring the clear orifices, all of which can cause vertigo. With improved living standards, people tend to eat high-salt, high-calorie diets, overeat, or overwork. These conditions damage the spleen and stomach, leading to the internal production of phlegm and dampness, which then invades the clear orifices, causing dizziness and headaches. This makes spleen deficiency and phlegm turbidity a common syndrome of hypertension. Therefore, hypertension due to spleen deficiency and phlegm turbidity is primarily characterized by spleen deficiency and phlegm turbidity as its symptoms. Treatment often involves both strengthening the spleen and resolving phlegm. Summary of the Invention

[0005] The present invention aims to provide a Chinese herbal compound composition for treating spleen deficiency and phlegm turbidity type hypertension and its preparation method, which has the effects of strengthening the spleen and resolving phlegm, promoting dampness and unblocking the meridians, lowering patients' blood pressure, improving patients' symptoms of dizziness and headache, and preventing the occurrence of cardiovascular and cerebrovascular diseases in patients with hypertension. To achieve the above objectives, the technical solutions of the present invention are as follows:

[0006] A traditional Chinese medicine compound composition for treating spleen deficiency and phlegm turbidity type hypertension and a preparation method thereof, comprising the following components in parts by mass:

[0007] 20-40 parts of raw astragalus, 10-20 parts of Poria, 10-20 parts of Alisma, 10-20 parts of Pueraria, 10-20 parts of Salvia miltiorrhiza, 5-10 parts of Chuanxiong, 10-20 parts of Leonurus, and 10-20 parts of Corn Silk.

[0008] Furthermore, a Chinese herbal compound composition for treating spleen deficiency and phlegm turbidity type hypertension comprises the following ingredients:

[0009] 30 parts of raw astragalus, 15 parts of Poria, 15 parts of Rhizoma Alismatis, 15 parts of Radix Puerariae, 15 parts of Salvia miltiorrhiza, 7 parts of Rhizoma Chuanxiong, 15 parts of Leonurus japonicus, and 15 parts of Corn Silk.

[0010] A method for preparing a traditional Chinese medicine compound composition for treating spleen deficiency and phlegm turbidity type hypertension comprises the following steps:

[0011] According to the above mass fractions, raw astragalus, Poria, Rhizoma Alismatis, Radix Puerariae, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Herba Leonurus, and Stigma Corni are added to 5 times their weight volume of water and decocted twice, each time for 1 to 2 hours. The decoctions are combined, filtered, and the filtrate is concentrated. 80% ethanol is added, the mixture is allowed to stand, filtered, recovered, and concentrated at 60°C to a relative density of 1.30 to 1.36 to obtain an extract. This extract can be prepared into a dosage form such as an ointment, oral solution, or granules by combining it with a pharmaceutically acceptable carrier.

[0012] The beneficial effects of the present invention are:

[0013] The present invention discloses a traditional Chinese medicine compound composition for treating hypertension caused by spleen deficiency and phlegm turbidity. This prescription primarily strengthens the spleen, resolves phlegm, and eliminates dampness, promoting the normal function of the spleen in transporting and transforming grain essence and qi, thereby distributing the essence of grain to all organs throughout the body. Adding blood-activating and blood-stasis-removing herbs can further prevent the spread of disease, normalize the function of various organs, balance yin and yang within the five internal organs, improve various symptoms, and normalize the flow of qi and fluid within the spleen and stomach. Astragalus membranaceus in the prescription is sweet and slightly warm in nature, primarily tonifying qi and raising yang, and is used to treat spleen and stomach qi deficiency and qi deficiency in the middle. Poria cocos is sweet, mild, and neutral in nature, primarily tonifying the spleen and promoting diuresis and eliminating dampness. The heavy use of Astragalus membranaceus in the prescription strengthens qi and spleen to transport and transform dampness, while the combination with Poria cocos enhances the spleen-strengthening and diuresis-controlling effects. Together, the two ingredients serve as the main ingredient, synergizing the function of distributing body fluid to all parts of the body. Alisma orientalis is sweet, mild, and cold in nature, primarily promoting diuresis and eliminating dampness. Pueraria root is sweet, pungent, and cool in nature, primarily promoting blood circulation and activating collaterals. Together, the two ingredients serve as the auxiliary ingredients, enhancing the function of promoting diuresis and promoting yang. Salvia miltiorrhiza is bitter and slightly cold, promoting blood circulation and removing blood stasis. Chuanxiong is pungent and warming, promoting blood circulation and qi mobilization. Leonurus japonicus is sweet, pungent, and slightly cold, clearing heat, promoting blood circulation, diuresis, and reducing swelling. These three herbs serve as adjuvants, working together to promote blood circulation and unblock the meridians. Corn silk, sweet and neutral, serves as a guiding agent, relieving restlessness and promoting diuresis. The entire formula combines both tonifying and purgative properties, addressing both the symptoms and the root cause, preventing further complications while simultaneously strengthening the spleen, activating blood circulation, and resolving phlegm and dampness. Specific embodiments

[0014] The present invention is a traditional Chinese medicine compound composition for treating spleen deficiency and phlegm turbidity type hypertension. The clinical manifestations of patients with this disease are as follows: when the clinic blood pressure is measured three times on different days without using antihypertensive drugs, the SBP is ≥140 mmHg and / or the DBP is ≥90 mmHg, accompanied by dizziness, headache, palpitations, insomnia, poor appetite and the like.

[0015] This embodiment provides a Chinese herbal compound composition for treating spleen deficiency and phlegm turbidity type hypertension, which is composed of the following components in parts by mass:

[0016] 30 parts of raw astragalus, 15 parts of Poria, 15 parts of Rhizoma Alismatis, 15 parts of Radix Puerariae, 15 parts of Salvia miltiorrhiza, 7 parts of Rhizoma Chuanxiong, 15 parts of Leonurus japonicus, and 15 parts of Corn Silk.

[0017] The preparation of the above-mentioned Chinese medicinal compound composition for treating spleen deficiency and phlegm turbidity type hypertension comprises the following steps:

[0018] According to the above mass fractions, 30g of raw Astragalus, 12g of Poria, 15g of Rhizoma Alismatis, 15g of Radix Puerariae, 12g of Salvia miltiorrhizae, 6g of Rhizoma Chuanxiong, 12g of Leonurus japonicus, and 12g of Stigma Zea Mays are taken, added with 5 times their weight volume of water, and decocted twice, each time for 1 to 2 hours. The decoctions are combined, filtered, and the filtrate is concentrated. 80% ethanol is added, allowed to stand, filtered, recovered, and concentrated at 60°C to a relative density of 1.30 to 1.36 to obtain an extract. This extract can be prepared with a pharmaceutically acceptable carrier into a dosage form such as an ointment, oral liquid, or granule.

[0019] The clinical effects of the Chinese herbal compound composition for treating spleen deficiency and phlegm turbidity type hypertension of the present invention are illustrated below through clinical trial examples.

[0020] Clinical data:

[0021] Research subjects: 100 patients with mild to moderate spleen deficiency and phlegm turbidity type hypertension admitted to Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine and Lishui District Hospital of Traditional Chinese Medicine from January 2022 to January 2024 were selected as research subjects and randomly divided into a control group (lifestyle intervention group), treatment group 1 (given the drug of the present invention twice a day), and treatment group 2 (given 100 mg of losartan potassium tablets once a day), with 50 cases in each group.

[0022] Inclusion criteria:

[0023] 1. Western Medicine Diagnostic Criteria: The diagnostic criteria for essential hypertension are based on the "Guidelines for the Prevention and Treatment of Hypertension in China" (2018 revised edition). Hypertension is defined as: SBP ≥ 140 mmHg and / or DBP ≥ 90 mmHg measured in the office on three different days, without antihypertensive medication. SBP ≥ 140 mmHg and DBP < 90 mmHg are considered isolated systolic hypertension. Patients with a history of hypertension currently taking antihypertensive medication should still be diagnosed with hypertension even if their blood pressure is below 140 / 90 mmHg.

[0024] 2. Traditional Chinese Medicine (TCM) diagnostic criteria: Refer to the TCM diagnostic criteria for hypertension in the "Guiding Principles for New Chinese Medicines" published in 2002, as well as the criteria for spleen deficiency and phlegm turbidity type hypertension established by TCM internal medicine. Main symptoms: dizziness, headache, a feeling of weight on the head, chest tightness, and vomiting of phlegm; Secondary symptoms: palpitations, insomnia, bland taste in the mouth, and poor appetite; Tongue and pulse: plump and tender tongue or with teeth marks on the edges, slippery, thin, or thick, greasy tongue coating, and a slippery or deep, stringy pulse. Note: Patients must have any three or more of the main symptoms, combined with tongue and pulse, for diagnosis; or they must have any two of the main symptoms and any two or more of the secondary symptoms, combined with tongue and pulse, for diagnosis.

[0025] Inclusion criteria: (1) Subjects who meet the diagnostic criteria for essential hypertension; (2) Subjects who meet the TCM syndrome differentiation criteria for spleen deficiency and phlegm turbidity; (3) Subjects aged between 18 and 80 years with complete clinical treatment data; (4) Subjects who volunteer to participate and sign the informed consent form.

[0026] Exclusion criteria: (1) Patients who are unable to cooperate with Chinese medicine treatment; (2) Pregnant and lactating women; (3) Patients who have taken related drug treatment within one month before the trial, such as adrenergic receptor agonists, glucocorticoids, etc.; (4) Patients with secondary hypertension (renal parenchymal hypertension, hypertension caused by renal artery stenosis and other vascular diseases, obstructive sleep apnea syndrome, primary aldosteronism, pheochromocytoma / paraganglioma, Cushing's syndrome, thyroid dysfunction, hyperparathyroidism), etc.; (5) Patients with hypertensive emergencies or subacuteness (primary or secondary hypertension patients have a sudden and significant increase in blood pressure (generally exceeding 180 / 120 mmHg) under certain inducements, accompanied or not with manifestations of progressive dysfunction of important target organs such as the heart, brain, and kidneys); (6) Patients with serious primary diseases of important organs (such as the heart, liver, kidneys, etc.) and the hematopoietic system, or mental illness; (7) Patients with allergic constitution or allergy to the trial drugs.

[0027] result

[0028] 1. Comparison of blood pressure indicators

[0029] Before treatment, there was no statistically significant difference in blood pressure between the control group and treatment group 1, or between treatment group 1 and treatment group 2 (P>0.05), indicating that there was no significant difference in the total TCM syndrome score between the two groups before treatment, indicating comparability. After treatment, the systolic blood pressure in the control group was (138.32±9.04) and the diastolic blood pressure in treatment group 1 was (87.78±8.85), while the systolic blood pressure in treatment group 1 was (125.84±7.85) and the diastolic blood pressure in treatment group 1 was (77.34±4.96). A paired sample t-test showed that the P values ​​for both systolic and diastolic blood pressure in both groups were <0.01, indicating statistically significant differences between the two groups. A comparison of the blood pressure efficacy between the two groups after treatment showed a P=0.000 (P<0.01) independent sample t-test, indicating statistically significant differences. This indicates that both the control group and treatment group 1 lowered blood pressure, with treatment group 1 showing superior efficacy compared to the control group. This suggests that the Chinese herbal composition of the present invention is significantly more effective in lowering blood pressure in treating spleen deficiency and phlegm turbidity-induced hypertension than the lifestyle intervention group.

[0030] After treatment, the systolic blood pressure in treatment group 1 was (125.84±7.85), and the systolic blood pressure in treatment group 2 was (128.48±6.95). A paired sample t-test showed that the P values ​​for systolic blood pressure in both groups were <0.01, indicating statistically significant differences. Comparison of the blood pressure efficacy between the two groups after treatment showed a P=0.075 (P>0.05) difference, indicating no statistically significant difference. This indicates that the control group, treatment group 1, and treatment group 2 had comparable antihypertensive effects. This suggests that the Chinese herbal composition of the present invention is comparable to oral losartan potassium tablets in lowering high blood pressure in the treatment of spleen deficiency and phlegm turbidity-induced hypertension.

[0031] Before treatment, there was no statistically significant difference in the total scores of TCM symptoms between the control group and treatment group 1, treatment group 1 and treatment group 2 (P>0.05), indicating that there was no significant difference in the total scores of TCM symptoms between the two groups of patients before treatment and they were comparable.

[0032] After treatment, the total TCM syndrome score in the control group was (15.3±4.14), and the total TCM syndrome score in treatment group 1 was (11.38±3.07). A paired sample t-test showed that the P values ​​for the total TCM syndrome scores in both groups were <0.01, indicating statistically significant differences. A comparison of the total TCM syndrome scores between the two groups after treatment showed a statistically significant difference of P=0.000 (P<0.01) using an independent sample t-test. This indicates that both the control group and treatment group 1 improved TCM syndromes, with treatment group 1 showing superior performance compared to the control group. This suggests that the Chinese herbal composition of the present invention is significantly superior to the lifestyle intervention group in improving TCM syndromes in treating spleen deficiency and phlegm turbidity-induced hypertension.

[0033] After treatment, the total TCM syndrome score for treatment group 1 was (11.38±3.07), and the total TCM syndrome score for treatment group 2 was (15.42±3.44). A paired sample t-test showed that the P values ​​for the total TCM syndrome scores in both groups were <0.01, indicating statistically significant differences. A comparison of the total TCM syndrome scores between the two groups after treatment showed a P=0.000 (P<0.01) difference in independent sample t-tests, indicating statistically significant differences. This indicates that both treatment groups 1 and 2 improved TCM syndromes, with treatment group 1 being superior to treatment group 2. This demonstrates that the traditional Chinese medicine composition of the present invention is significantly superior to oral losartan potassium tablets in improving TCM syndromes in treating spleen deficiency and phlegm turbidity hypertension. See Tables 1 and 2.

[0034]

[0035]

[0036] 2. Comparison of the efficacy of TCM syndromes among three groups

[0037] In terms of efficacy on TCM symptoms, the control group showed no significant effect, 15 effective cases, and an overall effective rate of 30%; treatment group 1 showed 5 significant effects, 39 effective cases, and an overall effective rate of 88%; treatment group 2 showed 3 significant effects, 34 effective cases, and an overall effective rate of 74%. This indicates that both the control and treatment groups improved TCM symptoms, with treatment group 1 being superior to the control group. This demonstrates that the TCM composition of the present invention is significantly superior to the lifestyle intervention group and the oral losartan potassium tablet group in improving TCM symptoms in treating spleen deficiency and phlegm turbidity hypertension (Table 3).

[0038]

[0039] 3. Comparison of the efficacy of TCM syndromes among three groups

[0040] Two patients experienced adverse reactions in treatment group 1, both of which were digestive symptoms. Four patients experienced adverse reactions in treatment group 2, including two cases of nausea, one case of fatigue, and one case of palpitations. This suggests that the Chinese herbal composition of the present invention is superior to the oral losartan potassium tablet group in reducing the incidence of adverse reactions in treating spleen deficiency and phlegm turbidity hypertension. (Table 4)

[0041]

[0042] 4. Prognosis

[0043] After 6 weeks of medication, 18 patients in treatment group 1 stopped taking antihypertensive drugs, and 5 patients in treatment group 2 stopped taking drugs, indicating that the Chinese medicine composition of the present invention is superior to the oral losartan potassium tablet group in improving the prognosis of hypertension in the treatment of spleen deficiency and phlegm turbidity type.

[0044] Typical medical cases

[0045] Case 1: Mr. Huang, male, 64 years old. Initial visit: March 18, 2023. Chief complaint: Dizziness, headache, poor appetite, and fatigue for one month. The patient had been experiencing dizziness and headache for the past month, along with poor appetite, fatigue, and bloating after meals. Blood pressure was 146 / 92 mmHg at the outpatient clinic. Due to a history of chronic renal insufficiency, the patient refused traditional Western antihypertensive medication. After taking this traditional Chinese medicine compound decoction for one month, his blood pressure fluctuated between 136-140 / 80-86 mmHg. The dizziness, headache, poor appetite, and fatigue disappeared, and the feeling of fullness after meals was significantly reduced.

[0046] Case 2: Yu, female, 63 years old. Initial visit: December 25, 2022. Chief complaint: dizziness for over two months. The patient had a history of hypertension for over two years and was taking amlodipine besylate 5mg once daily for treatment, with blood pressure well controlled. For the past two months, she had experienced occasional dizziness and discomfort, often after consuming greasy foods. Her blood pressure was 142 / 96 mmHg at the outpatient clinic. After two months of taking this traditional Chinese medicine compound decoction, her blood pressure fluctuated between 130-140 / 80-90 mmHg, and her dizziness resolved.

[0047] Case 3: Mr. Zhang, male, 71 years old. Initial visit: June 21, 2023. Chief complaint: dizziness for over a year. The patient has a history of hypertension for over 10 years, usually taking irbesartan tablets 150mg once daily. He has experienced occasional dizziness and headache for the past year. His blood pressure was 144 / 92 mmHg at the outpatient clinic. After taking this traditional Chinese medicine decoction for one month, his blood pressure fluctuated between 130-138 / 82-90 mmHg, and his dizziness and headache symptoms disappeared.

[0048] Case 4: Dong, female, 43 years old. First visit date: November 12, 2022. Chief complaint: dizziness for over 6 months. The patient has a history of hypertension and refuses antihypertensive medication. Her blood pressure fluctuates between 130-142 / 80-94 mmHg. In the past 6 months, she has experienced occasional dizziness and headache, accompanied by palpitations and shortness of breath after exercise. Her blood pressure was 142 / 94 mmHg at the outpatient clinic. After taking this Chinese herbal compound decoction for 2 months, her blood pressure fluctuated between 130-140 / 80-90 mmHg. The dizziness and headache, as well as the palpitations and shortness of breath after exercise, disappeared.

[0049] Case 5: Mr. Fang, male, 55 years old. Initial visit: August 21, 2023. Chief complaint: dizziness for over two months. The patient has a history of hypertension for over 10 years and is taking levamlodipine besylate 2.5mg once daily for treatment, with blood pressure well controlled. For the past two months, he has experienced occasional dizziness and discomfort, accompanied by poor appetite. Blood pressure at the outpatient clinic was 142 / 92 mmHg. After taking this traditional Chinese medicine compound decoction for one month, his blood pressure fluctuated between 130-140 / 80-90 mmHg, and his dizziness and poor appetite resolved.

[0050] in conclusion

[0051] As people's understanding of traditional Chinese medicine continues to deepen, the use of traditional Chinese medicine to treat modern diseases has become a trend of reform in the traditional Chinese medicine industry. Traditional Chinese medicine has unique advantages in treating hypertension. It focuses on combining symptoms with symptoms, treating both the symptoms and the root cause, and has a long-lasting and stable antihypertensive effect with minimal toxic and side effects. During the treatment process, it can effectively protect the patient's heart, brain, kidneys and other important organs. The Chinese medicine composition of the present invention has the effects of strengthening the spleen and resolving phlegm, promoting dampness and unblocking the meridians. It can lower the patient's blood pressure, improve dizziness and headache symptoms, and prevent the occurrence of cardiovascular and cerebrovascular diseases. The present invention is used in combination with traditional antihypertensive drugs, not only to synergistically enhance their antihypertensive effects, but also to provide a new treatment approach for patients who are intolerant to antihypertensive drugs. This prescription uses modern process technology to concentrate the active ingredients. The Chinese medicine paste and granules prepared are easy to carry, simple to take, and have significant effects. They will produce great social and economic benefits and lead the traditional Chinese medicine industry into the next generation.

Claims

1. A Chinese medicinal compound composition for treating spleen deficiency and phlegm turbidity type hypertension, characterized by: The medicine is prepared from the following raw medicines in parts by mass: 20-40 parts of raw astragalus, 10-20 parts of poria, 10-20 parts of oriental rhizome, 10-20 parts of kudzu root, 10-20 parts of salvia miltiorrhiza, 5-10 parts of ligusticum chuanxiong, 10-20 parts of motherwort and 10-20 parts of corn silk.

2. A Chinese medicine compound composition for treating spleen deficiency and phlegm turbidity type hypertension as claimed in claim 1, characterized in that: 30 parts of raw astragalus, 15 parts of Poria, 15 parts of Rhizoma Alismatis, 15 parts of Radix Puerariae, 15 parts of Salvia miltiorrhiza, 7 parts of Rhizoma Chuanxiong, 15 parts of Leonurus japonicus, and 15 parts of Corn Silk.

3. A method for preparing a Chinese medicine compound composition for treating spleen deficiency and phlegm turbidity type hypertension according to claim 1 or 2, characterized in that: The following steps are involved: According to the above-mentioned mass fractions, take raw astragalus, Poria, Alisma, Pueraria, Salvia miltiorrhiza, Chuanxiong, Leonurus japonicus, and corn silk, add 5 times the weight volume of water, decoct twice, each decoction for 1 to 2 hours, combine the decoctions, filter and concentrate the filtrate, add 80% volume concentration of ethanol for treatment, let it stand, filter and recover it, concentrate it at 60°C to a relative density of 1.30 to 1.36, and obtain an extract, which is prepared with a pharmaceutically acceptable carrier into a medicine in the form of ointment, oral liquid, or granule.

Images